Organization | Sansum Diabetes Research Institute

Sansum Diabetes Research Institute Report issue

Academic/Hospital Phase 4

Founded: Santa Barbara CA United States (1944)

Organization Overview

First Clinical Trial

2008

NCT01613807

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2021

Timeline

NOW

Now

Alternative names

Sansum Diabetes Research Institute

Active Ingredients

Drugs in Phase 4 Trials (5)

insulin degludec (tresiba) (1 trial)

insulin glargine (toujeo) (1 trial)

insulin human (humulin) (1 trial)

insulin lispro (humalog) (1 trial)

semaglutide (Ozempic) (1 trial)

Drugs in Other Trials (3)

high protein pasta (1 trial)

pasta (1 trial)

rice allergenic extract (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Diabetes, Gestational (Phase 4)

Diabetes Mellitus (Phase 4)

Diabetes Mellitus, Type 1 (Phase 4)

Overview

Highest Phase: Phase 4
# of Trials: 4
# of Trial APIs: 8